

12th November 2025

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Scrip Code: 531015

Subject: Outcome of Board Meeting, Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1. Submission of Unaudited Standalone Financial Results along with Auditors' Report for the quarter and half year ended 30th September, 2025:

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching herewith the Un-audited Standalone Financial Results along with Limited Review Report of the Statutory Auditors of the company, PPKG & Co Chartered Accountants for the quarter and half year ended 30th September, 2025 in Annexure-I.

The Financial Results are also available on the website of the Company at www.venmaxdrugs.com and on the website of BSE www.bseindia.com.

2. Other Matters Considered:

In continuation of the proposal for amalgamation of the Company with *M/s. Hatri Pharma Private Limited* (“Transferor Company”), which was approved by the Board of Directors on September 2, 2025, the Board of Directors, based on the recommendation of the Audit Committee, has considered and approved the financial statements as on September 30, 2025, for the purpose of valuation. The details are furnished in *Annexure-II*.

The Board Meeting commenced at 02:00 PM and concluded at 03:25 PM.

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

for Venmax Drugs & Pharmaceuticals Limited

**Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370**

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

Annexure -I

Statement of Financial Results for the Quarter and Half Year ended 30th September 2025

(RS. IN LAKHS)

Particulars		Quarter ended			Half year ended		Year Ended
		30/09/2025 (unaudited)	30/06/2025 (unaudited)	30/09/2024 (unaudited)	30/09/2025 (unaudited)	30/09/2024 (unaudited)	31/03/2025 (Audited)
I	Income						
I	Revenue from operations	131.85	121.03	17.13	252.87	27.53	80.73
II	Other income	-	-	-	-	3.00	105.32
	Total Revenue (I+II)	131.85	121.03	17.13	252.87	30.53	186.05
II	Expenses						
	Cost of materials consumed	-			-	-	-
	Purchases of Stock-in-Trade	258.41	112.25	20.00	370.66	30.27	85.21
	Change of Inventory	(143.97)	(3.18)	-	(147.15)	-	(5.75)
	Employee benefits expense	6.12	4.65	0.35	10.77	0.35	4.00
	Finance costs	0.06	0.01	0.08	0.08	0.08	0.08
	Depreciation and amortization expense	0.10	0.10	0.16	0.20	0.32	0.64
	Other expenses	6.61	3.46	26.97	10.06	28.87	103.28
	Total expenses	127.33	117.29	47.56	244.62	59.89	187.46
III	Profit before Exceptional items and tax						
	Exceptional Items	4.52	3.74	(30.43)	8.25	(29.35)	(1.41)
	Profit / (Loss) before tax	4.52	3.74	(30.43)	8.25	(29.35)	(1.41)
IV	Tax expense:						
	Current tax	2.08	-	-	2.08	-	-
	Deferred tax	(0.003)	-	0.015	(0.00)	0.01	(0.357)
	Profit/(loss) for the period from continuing operations	2.08	-	0.02	2.08	0.01	(0.36)
	Profit/(loss) from discontinued operations						
	Tax expense of discontinued operations						
	Profit/(loss) from Discontinued operations (After tax)						

V	Profit/(loss) for the year	2.44	3.74	(30.44)	6.18	(29.36)	(1.05)
	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Profit or Loss						
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss						
	B (i) Items that will be reclassified to Profit or Loss						
	(ii) Income tax relating to items that will be reclassified to Profit or Loss						
	Total Comprehensive Income for the period (Comprising Profit / (Loss)) and Other Comprehensive Income for the period						
VI	Earnings per Equity Share - Basic and Diluted	0.05	0.07	(0.581)	0.12	(0.560)	(0.02)

Notes to Accounts:

1. The above unaudited financial results of VENMAX DRUGS AND PHARMACEUTICALS LIMITED for the Quarter ended 30th September 2025 as reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 12th November, 2025. The Statutory Auditors of the Company have carried out a Limited Review on standalone financial results and expressed an unmodified conclusion thereon.
2. The Financial results have been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standard) Rules, 20105 (Ind AS), and other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India (SEBI).
3. The Company operates in single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.
4. Previous period figures have been reclassified and regrouped wherever considered necessary to confirm to the current period figures.

Place: Hyderabad
Date: 12th November, 2025

For Venmax Drugs and Pharmaceuticals Limited

**Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370**

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

Statement of Assets and Liabilities as at 30th September 2025

(Rs. In Lakhs)

Particulars	Notes	As at 30th September 2025, Unaudited	As at 31 March 2025, Audited
I. ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	3	3.85	4.05
(b) Capital Work-In-Progress			
(c) Intangible Assets			
(d) Financial Assets			
(i) Non-Current Investments			
(ii) Trade and Other Receivables			
(iii) Long Term Loans and Advances			
(d) Deferred Tax Assets (Net)			
(e) Other Non-Current Assets			
Non-Current Assets		3.85	4.05
(2) Current Assets			
(a) Inventories	4	152.90	5.75
(b) Financial Assets			
(i) Investments			
(ii) Trade and Other Receivables	5	347.12	95.26
(iii) Cash and Cash Equivalents	6	562.26	248.24
(iv) Short Term Loans and Advances	7	273.05	161.00
(c) Other Current Assets	8	25.50	2.67
Current Assets		1360.83	512.91
Total Assets		1364.68	516.96
I. EQUITY AND LIABILITIES			
(1) Equity			
(a) Share Capital	9	800.79	523.89
(b) Other Equity	10	56.93	(82.70)
Equity		857.72	441.19
(2) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Long Term Borrowings			

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

(b) Provisions				
(c) Deferred Tax Liabilities (Net)	11	0.10	0.10	0.10
(d) Other Non-current Liabilities				
Non-Current Liabilities		0.10	0.10	
(3) Current Liabilities				
(a) Financial Liabilities				
- Short term Borrowings	12	310.69	4.96	
-Other Financial Liabilities				
(i) Trade Payables				
Micro and small enterprises				
Other than micro and small enterprises	13	188.41	62.87	
(b) Short Term Provisions				
(c) Other Current Liabilities	14	7.76	7.84	
Current Liabilities		506.87	75.67	
Total Liabilities		1364.69		516.96

Place: Hyderabad

Date: 12th November, 2025

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

Cash Flow Statement for the Half year Ended 30th September 2025

(Rs. In Lakhs)

PARTICULARS	As at 30th Sep 2025	As at Mar 31, 2025
	Unaudited	Audited
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit as per Profit & Loss A/c	8.25	(1.41)
Adjustment for:		
Depreciation	0.20	0.64
Other comprehensive income	-	-
Loss on Sale / Discard of Intangible Assets (Net)		1.89
Net Operating Profit Before Working Capital	8.45	1.12
Changes		
Adjustment for:		
Trade & Other Receivables	(251.86)	(95.26)
Changes in inventory	(147.15)	(5.75)
Other Current Assets	(22.84)	(1.36)
Trade Payables	125.54	52.53
Other Financial liabilities	0.00	(10.82)
Other current liabilities	(0.08)	(6.24)
Provisions	0.00	(2.24)
Short Term Loans and Advances	(112.05)	(161.00)
Net Cash from Operating Activities	(399.98)	(229.02)
Direct taxes paid	2.08	0
Net Cash from Operating Activities	(402.06)	(229.02)
B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-	-
Sale of Fixed assets	-	-
Net Cash from Investing Activities	-	-
C) CASH FLOW FROM FINANCING ACTIVITIES		
Share application money pending allotment	415.35	507.26
Share Application money pending allotment money returned	(5.00)	

Proceeds from long/short term borrowings	305.73	(30.25)
Repayment of borrowings		
Net Cash from Financing Activities	716.08	477.01
Net Increase in Cash & Cash Equivalents	314.02	247.99
Add: Opening Cash & Cash Equivalents	248.24	0.25
Cash and Cash equivalents at the end of the year	562.26	248.24

Place: Hyderabad

Date: 12th November, 2025

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

Annexure – II

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sl. No	Particulars	Details
a)	Name of the entity(ies) forming part of the amalgamation/ merger, details in brief such as size, turnover etc.	<p>1. <u>Hatri Pharma Private Limited</u> (Un audited as on September 30, 2025)</p> <p>Net worth – INR 1610.00 Lakhs Turnover – INR 1846.41 Lakhs</p> <p>2. <u>Venmax Drugs and Pharmaceuticals Limited</u> (Un audited as on September 30, 2025)</p> <p>Net worth – INR 857.72 Lakhs Turnover – INR 252.87 Lakhs</p>
b)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms' length"	<p>No, the Company and the Transferor Company are not related parties to each other.</p> <p>In terms of General Circular No. 30/2014 dated July 17, 2014, issued by Ministry of Corporate Affairs ("MCA Circular"), the transactions arising out of compromises, arrangements and amalgamations under the Companies Act, 2013 ("Act"), will not attract the requirements of Section 188 of the Act.</p> <p>The consideration for the amalgamation will be discharged on an "arm's length" basis.</p>
c)	Area of business of the entity(ies)	<p>1. VDPL is engaged in Trading of pharmaceuticals products of Drug intermediates & fine chemicals</p> <p>2. HPPL is engaged in manufacturing of Drug intermediates and fine chemicals.</p>

d)	Rationale for amalgamation/ merger	<ul style="list-style-type: none"> a. The consolidation of entities with similar functions within the group, would result in, operational and administrative efficiencies, optimum utilization of infrastructure facilities and available resources, reduction in costs by focused operational efforts, rationalization, standardization, simplification of business processes and elimination of duplication. b. enhancement of operational, organizational and financial efficiencies, and achieve economies of scale by pooling of resources through backward integration; c. an integrated and coordinated approach to business and a more efficient allocation of capital and resources for growth opportunities; d. unification and streamlining off legal and regulatory compliances currently required to be carried out by both, the Transferor Company and the Transferee Company; e. consolidation of administrative and managerial functions and elimination of multiple record-keeping, <i>inter alia</i> other expenditure and optimal utilization of resources; and f. adaptation of best practices and in enhancing mechanization / automation of various processes through latest technologies. <p>The Scheme is in the interest of the Transferor Company and the Transferee Company and their respective stakeholders.</p>
e)	In case of cash consideration – amount or otherwise share exchange ratio	Upon the effectiveness of this Scheme and in consideration of the amalgamation of the Transferor Company with the Transferee Company, the Transferee Company shall, without any further application, act, deed, consent, acts, instrument or deed, discharge consideration, on a proportionate basis to each shareholder of the Transferor Company, whose name is recorded in the register of members as member of the Transferor Company as on the Effective Date or such person who has been recorded, in the records of a depository as on the Effective Date,

as the beneficial owner of such shares of the Transferor Company, and such shareholder shall be eligible to opt for consideration to be received in form of either:

1 (One) fully paid equity shares of INR 10 (Ten) each of the Transferee Company for every 1 (One) equity shares of INR 10 (Ten) held in the Transferor Company; **or**

The abovementioned consideration has been arrived based on Valuation Report and fairness opinion report obtained in this regard.

Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of The Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Venmax Drugs and Pharmaceuticals Limited

We have reviewed the accompanying Statement of unaudited financial results of Venmax Drugs and Pharmaceuticals Limited (the "Company") for the quarter and six months ended September 30, 2025 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO
Chartered Accountants
FRN: 0009655S


GIRDHARI LAL TOSHNIWAL
(Partner)
M.No-205140



Udin No: 259051408MOPHN2938

Place: Hyderabad
Date: 12/11/2025